Management of hepatitis B in China

Journal of Medical Virology

Volumn 61, Issue 3, 2000, Pages 392-397

  Yao, Guang Bi ^a  

^a Shanghai Jing An Qu Central Hospital   (China)

Author keywords

Chronic hepatitis B; Epidemiology; Lamivudine; Nucleoside analogue; Treatment; Vaccination

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; PLACEBO;

ANTIVIRAL ACTIVITY; ARTICLE; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEPATITIS B; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; VACCINATION;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CHINA; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; VARIATION (GENETICS);

DNA VIRUSES; HEPATITIS B VIRUS;

EID: 0342368972     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-9071(200007)61:3<392::AID-JMV19>3.0.CO;2-V     Document Type: Article

References (26)

1. Atkins M, Hunt CM, Brown N, Gray F, Sanathanan L, Woessner M, Lai CL, Dusheiko G, Dienstag J, Wright T, Barnard J, Bourne E, Condreay L. 1998. Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients. Hepatology 28:319A (Abstract 625).
2. Chang C-N, Skalski V, Zhou JH, Cheng Y. 1992. Biochemical pharmacology of (+)- and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J Biol Chem 267:22414-22420.
3. Cao HL. 1995. The studies of immune persistence and preventative efficacy after hepatitis B vaccination. Chin J Exp Clin Virol 9(Suppl):1-4
4. Cao HL, Xu ZY, Liu CB, et al. 1995 A cohort study of immune persistence and preventative efficacy in children after hepatitis B vaccination. Chin J Exp Clin Virol 9(Suppl):5-12
5. Dai ZC, Qi GM. 1997. The epidemiology characteristics of viral hepatitis B. In: Viral hepatitis in china: seroepidemiological survey in Chinese population (part one) 1992-1995. Beijing, China: Sci Tech Pub. p 39-59.
6. Dienstag J, Schiff E, Wright T, Perrillo R, Hann H-W, Crowther L, Woessner M, Rubin M, Brown N, US Lamivudine Investigator Group. 1998. Lamivudine treatment for one year in previously untreated US hepatitis B patients: histologic improvement and hepatitis Be-antigen (HBeAg) seroconversion. Gastroenterology 114:A1235 (Abstract L0148).
7. Furman PA, Davis M, Liotta DC, Paff M, Frick LW, Nelson DJ, Dornsife RE, Wurster JA, Wilson LJ, Fyfe JA, Tuttle JV, Miller WH, Condreay L, Averett DR, Schinazi RF, Painter GR. 1992. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother 36: 2686-2692.
8. Goodman Z, Dhillon AP, Wu PC, Gray F, Atkins M, Stevenson C, Barber J, Brown N, Crowther L, Woessner M. 1999. Lamivudine treatment reduces progression to cirrhosis in patients with chronic hepatitis B. J Hepatol 30:59 (Abstract GS5/26).
9. Hoofnagle JH, Di Bisceglie AM. 1997. The treatment of chronic viral hepatitis. N Engl J Med 336:347-356.
10. Johnson MA, Moore KHP, Yuen GJ, Bye A, Pakes GE. 1999. Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 36:41-66.
11. Lai C-L, Chien R-N, Leung NWY, Chang T-T, Guan R, Tai D-I, Ng K-Y, Wu P-C, Dent JC, Barber J, Stephenson SL, Gray DF, for the Asia Hepatitis Lamivudine Study Group. 1998. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 339:61-68.
12. Lai CL, Liaw YF, Leung NWY for the Asia Hepatitis Lamivudine Study Group, Deslauriers M, Barnard J, Sanathanan L, Gray DF, Condreay LD. 1997. Genotypic resistance to lamivudine in a prospective, placebo-controlled multicentre study in Asia of lamivudine therapy for chronic hepatitis B infection: incidence, kinetics of emergence, and correlation with disease parameters. Hepatology 26:259A (Abstract 522).
13. Leung N, Dienstag J, Schiff E, Sullivan M, Atkins M, Grice R, Woessner M, Brown N, Hunt CM. 1998. Clinical safety profile of lamivudine treatment in a large cohort of hepatitis B patients. Hepatology 28:587A (Abstract 1698).
14. Lok ASF, Lai C-L, Wu P-C, Leung EKY. 1988. Long-term follow-up in a randomised controlled trial of recombinant 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet 2:298-302.
15. Lok ASF, Wu P-C, Lai C-L, Lau JYN, Leung EKY, Wong LSK, Ma OCK, Lauder IJ, Ng CPL, Chung H-T. 1992. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 102:2091-2097.
16. Mast EE, Alter MJ. 1993. Epidemiology of viral hepatitis: an overview. Semin Virol 4:273-283.
17. Melegari M, Scaglioni PP, Wands JR. 1998. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628-633.
18. Schiff E, Karayalcin S, Grimm I, Perrillo R, Dienstag J, Husa P, Schalm S, Crowther L, Sullivan M, Woessner M, McPhillips P, Brown N, and the International Lamivudine Investigator Group. 1998. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy. Hepatology 28:388A (Abstract 901).
19. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray DF, and the Lamivudine Precore Mutant Study Group. 1999a. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 29:889-896.
20. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Gray DF, Barber J, Hawley S. 1999b. Post lamivudine treatment follow up of patients with HBeAg negative chronic hepatitis B. J Hepatol 30: 117 (Abstract P/C06/015).
21. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. 1993. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 119:312-323.
22. Xu ZY, Cao HL, Lia CB et al. 1995. A cross-section study of long-term effect of a universal infant hepatitis B vaccination programme. Chinese J Exp Clin Virol 9(Suppl):13-16.
23. Yao G. 1999. YMDD mutation in Chinese patients following lamivudine therapy for chronic hepatitis B infection. Gastroenterology 116:A848-A849 (Abstract G3689).
24. Yao G, Wang B, Cui Z, Yao J, Minde Z. 1999a. [Long-term efficacy of lamivudine in the treatment of hepatitis B patients]. Chinese J Hepatology 7:80-83 (in Chinese).
25. Yao G, Wang B, Cui Z, Yao J, Minde Z. 1999b. Long-term efficacy of lamivudine in the treatment of patients with chronic hepatitis B virus infection - a multicenter randomised, double-blind, placebo controlled trial. Gastroenterology 116:A848 (Abstract G3688).
26. Zhang D, for the Lamivudine Clinical Experts Guiding Group. 1999. [The Guiding opinion of the clinical application of lamivudine (first draft).] Chinese J Hepatol 3:189-190 (in Chinese).